Several data points for lebrikizumab (EBGLYSS; Lilly), a monoclonal antibody targeting interleukin-13, were reported at the 2025 American Academy of Dermatology (AAD) meeting held in Orlando, Florida ...
A look ahead to 5 key regulatory decisions scheduled to take place during the second quarter of 2025, from a monoclonal antibody to topical psoriasis treatments. As we transition into the second ...
Our editorial advisory board member Donna Hallas, , PPCNP-BC, CPNP, PMHS, FAANP, FAAN, highlights an article published in the March issue of Contemporary Pediatrics. Many parents may be using at-home ...
Mesoblast's remestemcel-L (Ryoncil) was approved by the FDA on December 18, 2024 to treat SR-aGVHD in patients 2 months and older. Now, it is available for purchase. The FDA-approved allogeneic (donor ...
A new clinical trial has found that omalizumab (Xolair; Genetech, Novartis) is more effective than oral immunotherapy (OIT) in treating multi-food allergy in individuals with severe allergic reactions ...
Fitusiran is administered subcutaneously starting once every 2 months for patients aged 12 years and older with hemophilia A or hemophilia B, with or without factor VIII or IX inhibitors. The FDA has ...
A surprise mimicker of a rare disorder: 13-year-old female with altered mental status ...
A surprise mimicker of a rare disorder: 13-year-old female with altered mental status ...
A surprise mimicker of a rare disorder: 13-year-old female with altered mental status ...
A surprise mimicker of a rare disorder: 13-year-old female with altered mental status ...
A surprise mimicker of a rare disorder: 13-year-old female with altered mental status ...
A surprise mimicker of a rare disorder: 13-year-old female with altered mental status ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback